ZLAB250117C22500
- 3.80
- +0.50+15.15%
Zai Lab Newsroom
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
Zai Lab Analyst Ratings
Leerink Partners Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $72
Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)
Zai Lab Is Maintained at Overweight by JP Morgan
Zai Lab Analyst Ratings
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $38
Jefferies Maintains Zai Lab(ZLAB.US) With Buy Rating, Cuts Target Price to $38
Strong Buy Rating for Zai Lab: Outperforming Vyvgart Sales and Promising Global Pipeline Fuel Optimism
Morgan Stanley Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $50
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $25
Buy Rating Affirmed for Zai Lab on Robust Drug Sales Growth and Strong Market Position
BofA Securities Maintains Zai Lab(ZLAB.US) With Buy Rating, Announces Target Price $25
Buy Rating Affirmed for Zai Lab on Strong Financials and Promising Pipeline Developments
Zai Lab Analyst Ratings
Bank of America Securities Sticks to Their Buy Rating for Zai Lab (ZLAB)
JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating
Zai Lab Analyst Ratings
Zai Lab Analyst Ratings